Parkinson’s Disease Therapeutics Market
The total diagnosed prevalence of Parkinson’s Disease is rising exponentially. The total diagnosed prevalent population of Parkinson’s disease in the 7MM (the US, EU5 (the UK, Germany, France, Italy, and Spain) and Japan) is expected to reach 3,284,084 in 2030.
The Parkinson’s disease therapeutics market lacks a curative approach and the burden continues to rise. Medications are at the place only to improve the main symptoms of the disease.
However, to tackle the situation some of the key pharmaceutical and biotech companies like Prevail Therapeutics, Axovant Gene Therapies, Neurocrine Biosciences/Voyager Therapeutics, Denali Therapeutics, International Stem Cell Corporation, Living Cell Technologies, and others have come up with their candidates that might prove to be a turning point in the Parkinson’s disease therapy market in the coming years.
Similarly, stem cell therapies, gene therapies, growth factors, and various other options are also in the clinical trials underway for the treatment of Parkinson’s disease.
Source: Parkinson’s Disease Therapeutics Market